LIFECORE BIOMEDICAL, INC. \DE\LFCR

LIFECORE BIOMEDICAL, INC. \DE\ Revenue Disclosure

10-KFiled Aug 7, 20252 min read
Revenue recognition
The Company disaggregates its revenue based on how it markets its products and services and reviews results of operations. The following table disaggregates revenues by major product lines and services:
Year ended
May 25, 2025May 26, 2024
CDMO$90,095 $96,616 
HA manufacturing38,772 31,645 
Total$128,867 $128,261 
The following table disaggregates revenues by the timing of revenue recognition:
Year ended
May 25, 2025May 26, 2024
Revenues recognized over time$23,194 $29,361 
Revenues recognized at a point in time105,673 98,900 
Total$128,867 $128,261 
During the fiscal year ended May 25, 2025, the Company had revenues concentrations of 10% or greater from three customers, with those customers comprising 44%, 18% and 10% of revenue. During the fiscal year ended May 26, 2024, the Company had revenues concentrations of 10% or greater from three customers, with those customers comprising 39%, 19% and 10% of revenue.
Contract assets primarily relate to the Company’s unconditional right to consideration for work completed but not billed at the reporting date. Contract liabilities primarily relate to payments received from customers in advance of performance under a contract.
The following table presents changes in contract assets and liabilities:
Contract assets, current
Contract liabilities, current
Contract liabilities, noncurrent
Balance at May 26, 2024$4,069 $(2,113)$(4,960)
Changes to the beginning balance arising from:
Amounts billed as accounts receivable as the result of rights to consideration becoming unconditional
(4,069)— — 
Recognition of revenue as the result of performance obligations satisfied
— 2,113 — 
Reclassification of scheduled satisfaction of performance obligations from noncurrent to current due to passage of time
— — 2,295 
Net change to contract balances recognized after the beginning of the period due to amounts billed, recognition of revenue, changes in estimate, reclassifications from noncurrent to current, and interest from significant financing component
6,979 (3,415)(360)
Balance at May 25, 2025$6,979 $(3,415)$(3,025)
Cash received in advance of services performed are recorded as deferred revenue.

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&ELeasesSegmentsDebtCommitmentsStock CompensationNew Standards